A large natural experiment study in Ontario, Canada, found that receiving the live attenuated herpes zoster vaccine significantly reduced the risk of a new dementia diagnosis by approximately 18% in adults aged 70 and older, providing the strongest evidence to date for a potential causal protective effect. The research leveraged a policy threshold where public funding for the vaccine was determined by birthdate (on or before January 1, 1946, or 1945), comparing the health outcomes of nearly identical groups born immediately on either side of this cutoff. Those eligible for vaccination had an absolute reduction in dementia risk of 2.0 percentage points over a 5.5-year follow-up period. The findings were further strengthened by a cross-province comparison showing that eligible birth cohorts in Ontario had significantly lower dementia incidence after the vaccination program began than matched cohorts in provinces without such a program. This evidence points to a promising public health strategy and suggests that investigating the neuroimmune mechanisms involved could offer new insights into dementia pathophysiology. Source: https://www.thelancet.com/
The American Cancer Society (ACS) concludes that the benefits of PSA-based screening for prostate cancer…
Proton pump inhibitor (PPI) use was modestly associated with incident dementia in older adults (pooled…
Extended follow-up of three major trials consistently shows that an initial invasive strategy does not…
Escitalopram, duloxetine, and agomelatine achieved higher sustained response rates than fluoxetine, while escitalopram and duloxetine…
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
This website uses cookies.